Replies to post #74963 on Bioelectronics Corp (BIEL)

[JustGoDeep]

Yup and in 5 short weeks that all changes. 200,000 surgical kits in the UK to start. How do you eat an elephant, answer one bite at a time.

[edbi46]

VERY, VERY, VERY IMPORTANT!!! NEWBIES!!
The Public Interest:

Biel is a great company with world class product. Biel is the owner of unique patented technologies using pulsed electromagnetic field. Biel is the only company in the world that provides this technology in a miniaturized size for various applications under product names such as Actipatch, Allay, Recoveryx and Smart Insole.

Biel's products are sold worldwide and awaiting FDA clearance for OTC and/or prescription as Class II products. In 2015, significant marketing efforts were done to penetrate the market place especially in the UK and Canada. As a result, Biel's products are now sold at major pharmacies and other places like Walgreens/Boots, Gordons Chemist, Costco Canada, Amazon, Showcase, superdrug, Lloyds Pharmacy, etc...

Biel may have 11 billion O/S and 15 billion A/S. At current share price the market value is 6.6 millions. Biel also carries debts that could amount to about 10 million dollars between IBEX and other entities. Reaching this threshold of where they are right now with this low amount of debt is a pretty significant accomplishment. IMO

[edbi46]

FACT !!!!!!!!!!!! -------
BioElectronics Drug-free Chronic Pain Therapy Observation Study Results

61% Pain Reduction & Decreases Medication Use in 86% (including opioids)


[29-March-2016]


FREDERICK, Md., March 29, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of the drug-free over-the-counter, $30.00 ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today the completion of a 6-month ActiPatch product observation study conducted in conjunction with its ongoing market research.
The study was conducted to measure the medical device's pain relief durability, its reduction of pain medication use, including prescription narcotic drugs, and its impact on the user's quality of life.
Out of the 254 chronic pain sufferers that participated, 224 completed the full 6-month study.
The key findings:
-Side effects: None reported
-Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.
-Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity and 71% reported their quality of life was much better to a great deal better.
-Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.
-Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.
-Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the Doctor and Pain Specialist.
The study has been accepted and will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK . The Company will also be exhibiting at the Congress: Booth #42.